School of Medicine and Pharmacology, The University of Western Australia, M503, 35 Stirling Highway, Crawley, WA, 6009, Australia.
Cancer Immunol Immunother. 2013 Mar;62(3):529-39. doi: 10.1007/s00262-012-1360-z. Epub 2012 Oct 16.
There is a complex interplay between the immune system and a developing tumor that is manifest in the way that the balance of T cell subsets in the local tumor environment reflects clinical outcome. Tumor infiltration by CD8(+) T cells and regulatory T cells (Treg) is associated with improved and reduced survival, respectively, in many cancer types. However, little is known of the prognostic value of immunological parameters measured in peripheral blood. In this study, peripheral CD8(+) T cells and Treg from 43 patients with malignant mesothelioma or advanced non-small-cell lung cancer scheduled to commence palliative chemotherapy were assessed by flow cytometry and evaluated for association with patient survival. Patients had a higher proportion of peripheral Treg, proliferating CD8(+) T cells and CD8(+) T cells with an activated effector phenotype compared with age-matched healthy controls. Higher proportions of Treg and proliferating CD8(+) T cells were both associated with poor survival in univariate analyses (hazard ratio [HR] 3.81, 95 % CI 1.69-8.57; p < 0.01 and HR 2.86, 95 % CI 1.26-6.50; p < 0.05, respectively). CD8(+) T cell proliferation was independently predictive of reduced survival in multivariate analysis (HR 2.58, 95 % CI 1.01-6.61; p < 0.05). These findings suggest that peripheral CD8(+) T cell proliferation can be a useful prognostic marker in patients with thoracic malignancies planned for palliative chemotherapy.
在免疫系统和发展中的肿瘤之间存在着复杂的相互作用，这种相互作用表现在局部肿瘤环境中 T 细胞亚群的平衡反映了临床结果。在许多癌症类型中，CD8(+)T 细胞和调节性 T 细胞（Treg）浸润肿瘤与改善和降低生存率分别相关。然而，对于外周血中测量的免疫参数的预后价值知之甚少。在这项研究中，通过流式细胞术评估了 43 名恶性间皮瘤或晚期非小细胞肺癌患者的外周血 CD8(+)T 细胞和 Treg，并评估了它们与患者生存的关系。与年龄匹配的健康对照组相比，患者的外周 Treg、增殖的 CD8(+)T 细胞和具有激活效应表型的 CD8(+)T 细胞比例更高。在单因素分析中，Treg 和增殖的 CD8(+)T 细胞的比例较高均与不良生存相关（风险比 [HR] 3.81，95%CI 1.69-8.57；p<0.01 和 HR 2.86，95%CI 1.26-6.50；p<0.05）。在多因素分析中，CD8(+)T 细胞增殖是独立预测生存时间缩短的因素（HR 2.58，95%CI 1.01-6.61；p<0.05）。这些发现表明，外周血 CD8(+)T 细胞增殖可能是计划进行姑息化疗的胸部恶性肿瘤患者的有用预后标志物。
